NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Royalty Pharma plc

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERRPRX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / RPRX COVERAGE

What’s moving Royalty Pharma plc now

Current reporting with the operating signal separated from the noise.

01
Royalty Pharma Plc (RPRX)

Royalty Pharma Plc (RPRX)

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: official volume, pricing, inventory and segment margin.
04
Royalty Pharma PLC (RPRX) hits fresh high: Is there still room to run?

Royalty Pharma PLC (RPRX) hits fresh high: Is there still room to run?

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Royalty Pharma plc: Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

Royalty Pharma plc: Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
06
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations

Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Royalty Pharma Plc Bottom Line Falls In Q3

Royalty Pharma Plc Bottom Line Falls In Q3

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
08
Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth

The story matters when it changes Royalty Pharma plc’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
09
Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript

Investors are testing whether Royalty Pharma plc’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest RPRX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-08-05 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-02-11 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-08-05 · Period 2026-08-05SEC ↗8-KMaterial company eventFiled 2026-06-04 · Period 2026-06-04SEC ↗8-KMaterial company eventFiled 2026-05-28 · Period 2026-05-22SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-10 · Period 2026-06-04SEC ↗144Official SEC filingFiled 2026-09-22SEC ↗
EARNINGS / QUARTERLY TRACKER

Royalty Pharma plc, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.